Brexit: Industry should keep Timelines for Batch Testing Facilities
In a reminder sent out to stakeholders the European Medicines Agency (EMA) points out that - independent from the extension of the date for the UK's withdrawal from the EU ('Brexit') to 31 October 2019 - Marketing Authorisation Holders (MAHs) should use the remaining time to complete all necessary preparations. This means that by 1 January 2020 all batch testing sites must be fully transferred to the remaining EU27 Member States and/or EEA countries. Also the necessary regulatory submissions must be completed by then. This includes MAHs who have the permission to perform quality control testing in the UK even after Brexit. "The transfer should be completed quickly and in principle by the end of 2019 at the latest", EMA writes on their website with Brexit related guidance documents. Companies should check this page regularly.
Related GMP News
25.06.2025Is Knowledge Management a Part of the Pharmaceutical Quality System?
11.06.2025Swissmedic differentiates GMP Scope for Manufacturing and Preparation for Administration
28.05.2025A View on the EU Critical Medicines Act to secure Pharma Supply Chains
20.05.2025Summary Data on Registration and Listing of Cosmetic Facilities and Products
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review